Abstract

Thyroid Cytology Smear Slides: An Untapped Resource for ThyroSeq Testing

Marina N. Nikiforova MD, Marcos Lepe MD, Lindsey A. Tolino BS, MBA, Megan E. Miller BS , N. Paul Ohori MD, Abigail I. Wald PhD, Michael S. Landau MD, Cihan Kaya PhD, Umberto Malapelle PhD, Claudio Bellevicine MD, PhD, Giancarlo Troncone MD, Yuri E. Nikiforov MD, PhD, Zubair Baloch MD, PhD

Background

Molecular testing of thyroid nodules with indeterminate fine-needle aspiration (FNA) cytology is commonly used to guide patient management and is typically performed on freshly collected FNA samples. In this study, the authors evaluated the performance of the ThyroSeq test in cytology smear slides

Methods

Air-dried Diff-Quik (DQ)-stained and alcohol-fixed Papanicolaou (Pap)-stained smears were used to determine required cellularity and sensitivity of mutation detection and to compare ThyroSeq v3 Genomic Classifier (GC) results obtained in cytology smears and fresh FNA samples from the same nodules.

Results

ThyroSeq testing of 31 cytology smears revealed that 25 smears (81%) were adequate for ThyroSeq analysis, including 14 Pap-stained smears (100%) and 11 DQ-stained smears (65%), whereas 6 DQ-stained smears (35%) failed RNA sequencing. The overall accuracy for detecting molecular alterations was 98%, with 100% concordance for mutations and gene expression alterations, 96% concordance for fusions, and 94% concordance for copy number alterations. Cytology smears were adequate for ThyroSeq analysis when at least 200 to 300 cells were present in 1 to 3 slides. ThyroSeq detected all studied mutations down to 5% allele frequency and BRAF mutations down to 1% allele frequency. Testing of smears yielded a positive ThyroSeq GC result in all nodules originally classified as positive.

Conclusions 

Thyroid FNA cytology smear slides with adequate cellularity can be successfully used for ThyroSeq GC testing in approximately 80% of cases, with an even higher success rate in Pap-stained smears. Compared with FNA samples collected into preservative solution, 94% to 100% of different genetic alterations could be accurately detected in smears, validating cytology smears as an alternative for ThyroSeq testing in patients with indeterminate thyroid cytology.

 

Source

Cancer Cytopathology. 2020; doi.org/10.1002/cncy.22331

Link To Full Article

https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncy.22331